vs
Side-by-side financial comparison of Gilead Sciences (GILD) and RYDER SYSTEM INC (R). Click either name above to swap in a different company.
RYDER SYSTEM INC is the larger business by last-quarter revenue ($13.1B vs $7.9B, roughly 1.7× Gilead Sciences). Gilead Sciences runs the higher net margin — 27.5% vs 0.7%, a 26.8% gap on every dollar of revenue. On growth, Gilead Sciences posted the faster year-over-year revenue change (4.7% vs 1.0%). Gilead Sciences produced more free cash flow last quarter ($3.1B vs $273.0M). Over the past eight quarters, RYDER SYSTEM INC's revenue compounded faster (102.9% CAGR vs 8.9%).
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir. Gilead is a member of the Nasdaq-100 and the S&P 100.
Ryder System, Inc. is an American transportation and logistics company, specializing in truck rental and leasing, fleet management, supply chain management, and transportation management. It also offers full-service leasing, rental and maintenance, used vehicle sales, transportation management, professional drivers, e-commerce fulfillment, and last-mile delivery services. The company is headquartered in Coral Gables, Florida, and operates in the United States and United Kingdom.
GILD vs R — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $7.9B | $13.1B |
| Net Profit | $2.2B | $93.0M |
| Gross Margin | 79.5% | — |
| Operating Margin | 25.0% | — |
| Net Margin | 27.5% | 0.7% |
| Revenue YoY | 4.7% | 1.0% |
| Net Profit YoY | 22.4% | -5.1% |
| EPS (diluted) | $1.75 | $2.34 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $13.1B | ||
| Q4 25 | $7.9B | $3.2B | ||
| Q3 25 | $7.8B | $3.2B | ||
| Q2 25 | $7.1B | $3.2B | ||
| Q1 25 | $6.7B | $3.1B | ||
| Q4 24 | $7.6B | $3.2B | ||
| Q3 24 | $7.5B | $3.2B | ||
| Q2 24 | $7.0B | $3.2B |
| Q1 26 | — | $93.0M | ||
| Q4 25 | $2.2B | $132.0M | ||
| Q3 25 | $3.1B | $138.0M | ||
| Q2 25 | $2.0B | $131.0M | ||
| Q1 25 | $1.3B | $98.0M | ||
| Q4 24 | $1.8B | $135.0M | ||
| Q3 24 | $1.3B | $142.0M | ||
| Q2 24 | $1.6B | $127.0M |
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | — | ||
| Q3 25 | 79.8% | — | ||
| Q2 25 | 78.8% | — | ||
| Q1 25 | 76.9% | — | ||
| Q4 24 | 79.1% | — | ||
| Q3 24 | 79.1% | — | ||
| Q2 24 | 77.8% | — |
| Q1 26 | — | — | ||
| Q4 25 | 25.0% | 5.6% | ||
| Q3 25 | 42.8% | 6.0% | ||
| Q2 25 | 34.9% | 5.8% | ||
| Q1 25 | 33.6% | 4.3% | ||
| Q4 24 | 32.4% | 5.7% | ||
| Q3 24 | 11.8% | 5.9% | ||
| Q2 24 | 38.0% | 5.6% |
| Q1 26 | — | 0.7% | ||
| Q4 25 | 27.5% | 4.2% | ||
| Q3 25 | 39.3% | 4.4% | ||
| Q2 25 | 27.7% | 4.1% | ||
| Q1 25 | 19.7% | 3.1% | ||
| Q4 24 | 23.6% | 4.2% | ||
| Q3 24 | 16.6% | 4.5% | ||
| Q2 24 | 23.2% | 4.0% |
| Q1 26 | — | $2.34 | ||
| Q4 25 | $1.75 | $3.22 | ||
| Q3 25 | $2.43 | $3.32 | ||
| Q2 25 | $1.56 | $3.13 | ||
| Q1 25 | $1.04 | $2.27 | ||
| Q4 24 | $1.43 | $3.09 | ||
| Q3 24 | $1.00 | $3.24 | ||
| Q2 24 | $1.29 | $2.84 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.0M | $182.0M |
| Total DebtLower is stronger | $24.9B | — |
| Stockholders' EquityBook value | $22.7B | $2.9B |
| Total Assets | $59.0B | — |
| Debt / EquityLower = less leverage | 1.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $182.0M | ||
| Q4 25 | $68.0M | $198.0M | ||
| Q3 25 | $19.0M | $189.0M | ||
| Q2 25 | $69.0M | $180.0M | ||
| Q1 25 | — | $151.0M | ||
| Q4 24 | — | $154.0M | ||
| Q3 24 | — | $162.0M | ||
| Q2 24 | — | $164.0M |
| Q1 26 | — | — | ||
| Q4 25 | $24.9B | $6.8B | ||
| Q3 25 | $24.9B | $7.3B | ||
| Q2 25 | $24.9B | $7.0B | ||
| Q1 25 | $25.0B | $6.7B | ||
| Q4 24 | $26.7B | $6.7B | ||
| Q3 24 | $23.2B | $6.6B | ||
| Q2 24 | $23.3B | $6.5B |
| Q1 26 | — | $2.9B | ||
| Q4 25 | $22.7B | $3.1B | ||
| Q3 25 | $21.5B | $3.1B | ||
| Q2 25 | $19.7B | $3.1B | ||
| Q1 25 | $19.2B | $3.0B | ||
| Q4 24 | $19.3B | $3.1B | ||
| Q3 24 | $18.5B | $3.1B | ||
| Q2 24 | $18.3B | $3.1B |
| Q1 26 | — | — | ||
| Q4 25 | $59.0B | $16.4B | ||
| Q3 25 | $58.5B | $16.5B | ||
| Q2 25 | $55.7B | $16.5B | ||
| Q1 25 | $56.4B | $16.4B | ||
| Q4 24 | $59.0B | $16.7B | ||
| Q3 24 | $54.5B | $16.5B | ||
| Q2 24 | $53.6B | $16.4B |
| Q1 26 | — | — | ||
| Q4 25 | 1.10× | 2.24× | ||
| Q3 25 | 1.16× | 2.35× | ||
| Q2 25 | 1.27× | 2.27× | ||
| Q1 25 | 1.30× | 2.21× | ||
| Q4 24 | 1.38× | 2.14× | ||
| Q3 24 | 1.26× | 2.17× | ||
| Q2 24 | 1.28× | 2.09× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $3.3B | $583.0M |
| Free Cash FlowOCF − Capex | $3.1B | $273.0M |
| FCF MarginFCF / Revenue | 39.4% | 2.1% |
| Capex IntensityCapex / Revenue | 2.6% | 3.3% |
| Cash ConversionOCF / Net Profit | 1.52× | 6.27× |
| TTM Free Cash FlowTrailing 4 quarters | $9.5B | $595.0M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $583.0M | ||
| Q4 25 | $3.3B | $749.0M | ||
| Q3 25 | $4.1B | $442.0M | ||
| Q2 25 | $827.0M | $752.0M | ||
| Q1 25 | $1.8B | $651.0M | ||
| Q4 24 | $3.0B | $558.0M | ||
| Q3 24 | $4.3B | $629.0M | ||
| Q2 24 | $1.3B | $552.0M |
| Q1 26 | — | $273.0M | ||
| Q4 25 | $3.1B | $344.0M | ||
| Q3 25 | $4.0B | $-85.0M | ||
| Q2 25 | $720.0M | $63.0M | ||
| Q1 25 | $1.7B | $137.0M | ||
| Q4 24 | $2.8B | $-201.0M | ||
| Q3 24 | $4.2B | $30.0M | ||
| Q2 24 | $1.2B | $-87.0M |
| Q1 26 | — | 2.1% | ||
| Q4 25 | 39.4% | 10.8% | ||
| Q3 25 | 51.0% | -2.7% | ||
| Q2 25 | 10.2% | 2.0% | ||
| Q1 25 | 24.8% | 4.4% | ||
| Q4 24 | 37.4% | -6.3% | ||
| Q3 24 | 55.2% | 0.9% | ||
| Q2 24 | 17.2% | -2.7% |
| Q1 26 | — | 3.3% | ||
| Q4 25 | 2.6% | 12.8% | ||
| Q3 25 | 1.9% | 16.6% | ||
| Q2 25 | 1.5% | 21.6% | ||
| Q1 25 | 1.6% | 16.4% | ||
| Q4 24 | 1.9% | 23.8% | ||
| Q3 24 | 1.9% | 18.9% | ||
| Q2 24 | 1.9% | 20.1% |
| Q1 26 | — | 6.27× | ||
| Q4 25 | 1.52× | 5.67× | ||
| Q3 25 | 1.35× | 3.20× | ||
| Q2 25 | 0.42× | 5.74× | ||
| Q1 25 | 1.34× | 6.64× | ||
| Q4 24 | 1.67× | 4.13× | ||
| Q3 24 | 3.44× | 4.43× | ||
| Q2 24 | 0.82× | 4.35× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GILD
| Other | $3.4B | 43% |
| HIV Products Biktarvy | $3.3B | 41% |
| HIV Products Odefsey | $239.0M | 3% |
| Liver Disease Products Other Liver Disease | $170.0M | 2% |
| HIV Products Other HIV | $155.0M | 2% |
| Other Products Yescarta | $150.0M | 2% |
| Liver Disease Products Vemlidy | $149.0M | 2% |
| Liver Disease Products Sofosbuvir Velpatasvir | $140.0M | 2% |
| HIV Products Symtuza Revenue Share | $98.0M | 1% |
| Veklury | $80.0M | 1% |
| Cell Therapy Products Tecartus | $32.0M | 0% |
| Royalty Contract And Other | $22.0M | 0% |
R
Segment breakdown not available.
